The Alzheimer’s disease–linked protease BACE2 modulates lymphangiogenic VEGFR3 signaling, and BACE2-cleaved soluble VEGFR3 has utility as a pharmacodynamic plasma marker for BACE2 activity in vivo. This evidence concerns the gene FLT4 and early-onset autosomal dominant Alzheimer disease.